Research
Hormonal
Retatrutide treatment for 48 weeks resulted in a least-squares mean percentage change in body weight of -24.2% in the 12 mg group compared to -2.1% in the placebo group.
Retatrutide may be an effective treatment option for significant weight loss in adults with obesity.
StrongSupportsmedium confidence
At 48 weeks, the least-squares mean percentage change in the retatrutide groups was -24.2% in the 12-mg group, as compared with -2.1% in the placebo group.
Why this rating
Based on a phase 2, double-blind, randomized, placebo-controlled trial design.
Source
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Ania M. Jastreboff et al. · New England Journal of Medicine · 2023
DOI 10.1056/nejmoa2301972
rct · n=338Cited 940×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →